Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Collaborative Health Research Projects

McMaster University

$200,500.00

Development of Molecularly Targeted Ultrasound Contrast Agents for Prostate Cancer Imaging using Bioorthogonal Chemistry

FY 2017-18

Summary
Current imaging and biopsy methods for the detection of prostate cancer have major limitations that impact patient outcomesand can lead to unnecessary treatments. These include the use of ineffective therapies, or unnecessary and life-altering sideeffects being experienced by patients, resulting in added and unnecessary expense and burden to the healthcare system.The aim of the proposed study is to overcome these limitations by using ultrasound imaging, together with a new generationof targeted contrast agents that bind to prostate cancer cells, but not to normal tissue. The microbubble contrast agentsutilize a new targeting technology that allows them to collect only in aggressive tumors, resulting in an enhanced ultrasoundsignal. With this approach, it will be possible to properly identify those patients that need immediate and more aggressivetreatment, from those that can opt for active surveillance. It will also create a tool to help better guide biopsies, in order tominimize sampling errors and the need to repeat procedures, which at present happen too frequently. The availability ofultrasound technology in most cancer centers makes this approach both feasible and highly useful for detection andmonitoring of prostate cancer.The project will be accomplished through collaboration between a chemistry group at McMaster University and an ultrasoundimaging group at Sunnybrook Hospital. Students from science and health science fields will work in teams to carry out thespecific aims. The proposal is supported by strong preliminary research and the active participation of a Canadianultrasound imaging company and a national centre of excellence, whose expertise ensure that the new technologies canquickly move from the laboratory to the clinic, and ultimately to the market. The results of this project could bring a paradigmshift in how prostate cancer patients are diagnosed, and at the same time reduce unnecessary treatments and improvingoutcomes.
Program
Collaborative Health Research Projects
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data

As published

Application id
493840-2016
Name nom
Valliant, John
Department département
Chemistry & Chemical Biology
Organization id
27
Institution établissement
McMaster University
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2017
Competition year année de concours
2016
Award amount
200500
Program id
CHRPJ
Program name en
Collaborative Health Research Projects
Program name fr
Projets de recherche concertée sur la santé
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
360
Committee name en
Collaborative Health Research Projects Selection Panel
Committee name fr
Comité de sélection de projets de recherche concertée sur la santé
Area of application code
9999
Area of application group en
Not available
Area of application group fr
Non disponible
Area of application en
Not available
Area of application fr
Non disponible
Research subject code
9999
Research subject group en
Not available
Research subject group fr
Non disponible
Research subject en
Not available
Research subject fr
Non disponible
Partie
2 & 3
Nb partie
3
Application title
Development of Molecularly Targeted Ultrasound Contrast Agents for Prostate Cancer Imaging using Bioorthogonal Chemistry
Keyword
NSERC
Application summary
Current imaging and biopsy methods for the detection of prostate cancer have major limitations that impact patient outcomesand can lead to unnecessary treatments. These include the use of ineffective therapies, or unnecessary and life-altering sideeffects being experienced by patients, resulting in added and unnecessary expense and burden to the healthcare system.The aim of the proposed study is to overcome these limitations by using ultrasound imaging, together with a new generationof targeted contrast agents that bind to prostate cancer cells, but not to normal tissue. The microbubble contrast agentsutilize a new targeting technology that allows them to collect only in aggressive tumors, resulting in an enhanced ultrasoundsignal. With this approach, it will be possible to properly identify those patients that need immediate and more aggressivetreatment, from those that can opt for active surveillance. It will also create a tool to help better guide biopsies, in order tominimize sampling errors and the need to repeat procedures, which at present happen too frequently. The availability ofultrasound technology in most cancer centers makes this approach both feasible and highly useful for detection andmonitoring of prostate cancer.The project will be accomplished through collaboration between a chemistry group at McMaster University and an ultrasoundimaging group at Sunnybrook Hospital. Students from science and health science fields will work in teams to carry out thespecific aims. The proposal is supported by strong preliminary research and the active participation of a Canadianultrasound imaging company and a national centre of excellence, whose expertise ensure that the new technologies canquickly move from the laboratory to the clinic, and ultimately to the market. The results of this project could bring a paradigmshift in how prostate cancer patients are diagnosed, and at the same time reduce unnecessary treatments and improvingoutcomes.